FDA DEVICE FACTS
Helix Genetic Health Risk App for late-onset Alzheimer’s disease
Helix Opco, LLC
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Helix Genetic Health Risk App (HRA) uses qualitative genoty ping to detect clinically relevant variants in genomic DNA isolated from human saliva collected from individuals ≥18 years with Oragene ®•Dx OGD- 610 for the purpose of reporting and interpreting Genetic Health Risks (GHR): The Helix Genetic Health Risk App (HRA) for late-onset Alzheime r’s disease is indicated for reporting of the e2/e2, e2/e3, e3/ e3, e2/e4, e3/e4 and e4/e4 genotypes in the APOE gene. The repo rt describes if a person's genetic result is associated with an increased or decreased risk of developing late-onset Alzheim er’s disease. The e2 and e4 variants included in this report are found and have been studied in many ethnicities. Detailed r isk estimates have been studied the most in people of European descent. The Helix Genetic Health Risk App (HRA) is to be used with the Helix Laboratory Platform.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。